|
1
|
Fenaux P, Mufti GJ, Hellstrom-Lindberg E,
Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz
G, List A, et al: Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: A randomised, open-label, phase III
study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uchida T, Ogawa Y, Kobayashi Y, Ishikawa
T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, et
al: Phase I and II study of azacitidine in Japanese patients with
myelodysplastic syndromes. Cancer Sci. 102:1680–1686. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2406.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheson BD, Greenberg PL, Bennett JM,
Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM,
Stone RM, et al: Clinical application and proposal for modification
of the International Working Group (IWG) response criteria in
myelodysplasia. Blood. 108:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silverman LR, Demakos EP, Peterson BL,
Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D,
Powell BL, DeCastro CM, et al: Randomized controlled trial of
azacitidine in patients with the myelodysplastic syndrome: A study
of the cancer and leukemia group B. J Clin Oncol. 20:2429–2440.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Helm LH, Alhan C, Wijermans PW,
van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn
M, van Rees BP, de Weerdt O, et al: Platelet doubling after the
first azacitidine cycle is a promising predictor for response in
myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia
(CMML) and acute myeloid leukaemia (AML) patients in the Dutch
azacitidine compassionate named patient programme. Br J Haematol.
155:599–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujimaki K, Miyashita K, Kawasaki R and
Tomita N: Efficacy and safety of a 5-day regimen of azacitidine for
patients with high-risk myelodysplastic syndromes. Eur J Haematol.
97:228–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morita Y, Maeda Y, Yamaguchi T, Urase F,
Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura
I and Matsuda M: Five-day regimen of azacitidine for lower-risk
myelodysplastic syndromes (refractory anemia or refractory anemia
with ringed sideroblasts): A prospective single-arm phase 2 trial.
Cancer Sci. 109:3209–3215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lyons RM, Cosgriff TM, Modi SS, Gersh RH,
Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT and
Beach CL: Hematologic response to three alternative dosing
schedules of azacitidine in patients with myelodysplastic
syndromes. J Clin Oncol. 27:1850–1856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ugai T, Matsuo K, Sawada N, Iwasaki M,
Yamaji T, Shimazu T, Sasazuki S, Inoue M, Kanda Y and Tsugane S;
Japan Public Health Centre-based Prospective Study Group, : Smoking
and alcohol and subsequent risk of myelodysplastic syndromes in
Japan: The Japan Public Health Centre-based Prospective Study. Br J
Haematol. 178:747–755. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beguin Y, Selleslag D, Meers S, Graux C,
Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, et
al: Safety and efficacy of azacitidine in Belgian patients with
high-risk myelodysplastic syndromes, acute myeloid leukaemia, or
chronic myelomonocytic leukaemia: results of a real-life,
non-interventional post-marketing survey. Acta Clin Belg. 70:34–43.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
The NCCN Clinical Practice Guidelines in
Oncology, Myelodysplastic Syndromes, Version2.20 2019-October18.
2018, https://www.nccn.org/professionals/physician_gls/pdf/mds.pdfNovember
11–2018
|
